Andy Pasternak Sells 27,129 Shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP) Stock

Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) EVP Andy Pasternak sold 27,129 shares of the firm’s stock in a transaction that occurred on Tuesday, January 17th. The stock was sold at an average price of $113.03, for a total transaction of $3,066,390.87. Following the sale, the executive vice president now directly owns 56,338 shares of the company’s stock, valued at approximately $6,367,884.14. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Horizon Therapeutics Public Price Performance

Shares of NASDAQ:HZNP opened at $113.06 on Friday. The company has a current ratio of 3.96, a quick ratio of 3.74 and a debt-to-equity ratio of 0.51. The stock’s fifty day simple moving average is $101.40 and its two-hundred day simple moving average is $80.14. Horizon Therapeutics Public Limited has a 1-year low of $57.84 and a 1-year high of $117.49. The stock has a market cap of $25.62 billion, a PE ratio of 46.34, a price-to-earnings-growth ratio of 1.74 and a beta of 1.16.

Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) last issued its quarterly earnings data on Wednesday, November 2nd. The biopharmaceutical company reported $1.25 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.25. Horizon Therapeutics Public had a return on equity of 24.59% and a net margin of 15.51%. The business had revenue of $925.36 million for the quarter, compared to analysts’ expectations of $888.93 million. As a group, analysts forecast that Horizon Therapeutics Public Limited will post 4.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HZNP has been the subject of several recent analyst reports. Jefferies Financial Group raised their price objective on shares of Horizon Therapeutics Public from $101.00 to $125.00 in a research report on Thursday, December 1st. BMO Capital Markets downgraded shares of Horizon Therapeutics Public from an “outperform” rating to a “market perform” rating in a research report on Tuesday, December 13th. HC Wainwright initiated coverage on shares of Horizon Therapeutics Public in a research report on Tuesday, November 1st. They set a “neutral” rating and a $74.00 price objective for the company. Piper Sandler downgraded shares of Horizon Therapeutics Public from an “overweight” rating to a “neutral” rating in a research report on Monday, December 12th. Finally, Wells Fargo & Company downgraded shares of Horizon Therapeutics Public from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $118.00 to $116.50 in a research report on Monday, December 12th. Eight equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $111.42.

Hedge Funds Weigh In On Horizon Therapeutics Public

Large investors have recently bought and sold shares of the stock. CoreCap Advisors LLC bought a new position in Horizon Therapeutics Public during the 2nd quarter valued at $33,000. Allworth Financial LP lifted its stake in Horizon Therapeutics Public by 936.7% during the 3rd quarter. Allworth Financial LP now owns 622 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 562 shares in the last quarter. CI Investments Inc. lifted its stake in Horizon Therapeutics Public by 75.9% during the 3rd quarter. CI Investments Inc. now owns 628 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 271 shares in the last quarter. Steward Financial Group LLC bought a new position in Horizon Therapeutics Public during the 2nd quarter valued at $41,000. Finally, Samalin Investment Counsel LLC bought a new stake in shares of Horizon Therapeutics Public during the 1st quarter worth $41,000. 91.01% of the stock is currently owned by institutional investors.

About Horizon Therapeutics Public

(Get Rating)

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.